CombiMatrix, Clarient to market and sell cancer test

Jan 31 (Reuters) - CombiMatrix Corp (CBMX.O) and Clarient Inc (CLRT.O) said they would jointly market and sell a cancer test called HemeScan.

HemeScan test will be marketed by Clarient to pathologists, oncologists and patients, CombiMatrix said in a statement.

The HemeScan test is a comprehensive test which enables prognosis at the time of diagnosis in the treatment and care of chronic lymphocytic leukemia patients. (Reporting by Bhaswati Mukhopadhyay in Bangalore; Editing by Amitha Rajan)